PeptidPro: Slavinorm

Main article: Atherosclerosis

2022: Entering the market and obtaining state registration

On June 27, 2022, PeptidPRO announced that it would enter the market and receive state registration for three injectable drugs: Vesusten, Fertiwell, Slavinorm. Read more here.

According to the company, Slavinorm is an injectable drug for the pathogenetic treatment of COSANK, which, thanks to a complex cascade mechanism of action, affects the main causes of the development of atherosclerosis and increases the distance of pain-free walking, ensuring an increase in the therapeutic effect even after the end of the course of therapy.

Slavinorm is a prescription injectable drug for the pathogenetic treatment of stage I-II COSANK according to the Fontaine classification with a cascading mechanism of action. The drug is used to increase the distance of pain-free walking in adult patients.

A multicenter, double-blind, placebo-controlled randomized trial (CS SLV-07-2018 report) of Slavinorm concluded that Slavinorm had superior efficacy over placebo for a 50% increase in walking distance.

Based on the results of randomized, double-blind, placebo-controlled clinical trials (CS SLV-07-20185 and SLV-12-2019 reports), the course use of Slavinorm not only increased the distance of pain-free walking, but also increased the ankle-shoulder index (LPI) by more than 10% (difference with placebo - by 4 times, p = 0.000092; moreover, both the drug and placebo were administered against the background of compulsory standard therapy of COSANK);

In multicenter, double-blind, placebo-controlled randomized trials (CS SLV-07-20185 and SLV-12-20196 reports), the incidence of adverse events in Slavinorm has been shown to be comparable to placebo.